The U.S. Treasury Department took new steps on Monday to curb tax-avoiding corporate "inversions," with the pending $160 billion merger of Pfizer Inc and Allergan Plc seen as a potential casualty.
lundi 4 avril 2016
Inscription à :
Publier les commentaires (Atom)
0 commentaires:
Enregistrer un commentaire